Skin Substitutes in Wound Care: Powerful Tools or Growing Controversy?
Summary: In a candid conversation, Dr. John Steinberg and Dr. Ben Pearl discuss the current state of skin substitutes (also known as Cellular and/or Tissue-Based Products – CTPs). They emphasize that these advanced skin replacement grafts are highly effective tools for hard-to-heal diabetic foot ulcers (DFUs) and venous leg ulcers when standard of care fails. However, they also raise strong concerns about dramatic price inflation, rebate/kickback practices, and the risk that widespread abuse could lead to restricted access or payer backlash that harms legitimate patient care.
Key Highlights:
- Skin substitutes can significantly accelerate healing and help prevent amputations in chronic, non-healing wounds
- Strong clinical evidence supports their use in appropriate patients after adequate debridement, offloading, and vascular optimization
- Major concern: Some products are billed at extremely high prices (e.g., tens of thousands of dollars) with questionable added value
- Warning that unethical pricing and rebate practices may trigger severe reimbursement restrictions, limiting access for patients who truly benefit
- Call for responsible use, transparent pricing, and focus on proven clinical outcomes
Watch the full discussion (YouTube Short)
Clinical Takeaway: Skin substitutes remain a valuable advanced therapy in modern wound care when used judiciously. The challenge for the field is to preserve access to these effective tools while addressing pricing and utilization issues that threaten their long-term viability.
Keywords: skin substitutes, CTPs wound care, diabetic foot ulcer grafting, skin replacement therapy, John Steinberg